Gen1e Lifesciences Inc.

Leland Stanford Junior University

Genie Lifesciences Inc.

University System of Maryland

Ritu Lal

Adam Galan

Wendy Luo

John Eric Paderi

Brian T Kannard

Peter Luke Santa Maria

Abhinav Ramani

Brian Hsueh

Alexander D MacKerell, Jr

Steven Fletcher

Paul S Shapiro

Nathan Larson

Chakk Ramesha

Peter Santa Maria

John Paderi

Brian Kannard

The compound 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate, pharmaceutical compositions thereof, and use of the compound and the pharmaceutical compositions for treating cancer and pulmonary diseases are disclosed.

Inhibitors of extracellular signal-regulated kinase

Substituted naphthyl p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the substituted naphthyl p38α mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereof for treating diseases are disclosed.

Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors

Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide dihydrochloride dihydrate, methods of preparing the crystalline salt, pharmaceutical compositions containing the crystalline salt, and methods of treatment using the crystalline salt are disclosed.

Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate

Crystalline 4-chloro-N-(4-(morpholinomethyl)phenyl)benzamide, crystalline 4-chloro-N-(4-(morpholinomethyl)phenyl)benzamide hydrochloride, methods of preparing the crystalline compounds, pharmaceutical compositions containing the crystalline compounds, and methods of treatment using the crystalline compounds are disclosed.

Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt

Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors

Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38α mitogen-activated protein kinase inhibitors.

P38α mitogen-activated protein kinase inhibitors

Substituted naphthyl p38&#x3b1; mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the substituted naphthyl p38&#x3b1; mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereof for treating diseases are disclosed.

Substituted naphthyl p38&#x3b1; mitogen-activated protein kinase inhibitors

Disclosed herein are p38&#x3b1; mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38&#x3b1; mitogen-activated protein kinase inhibitors.

p38&#x3b1; mitogen-activated protein kinase inhibitors

Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate

P38&#x3b1; mitogen-activated protein kinase inhibitors

A method for maintaining and/or increasing body temperature of a patient may involve delivering heat to a first location on a limb of the patient, delivering heat to a second location on the limb, apart from the first location, and applying intermittent compression to a third location on the limb, located between the first location and the second location. A device for maintaining and/or increasing body temperature of a patient may include a sleeve for positioning over at least part of one of the patient's limbs, first and second heat delivery members coupled with the sleeve, and an intermittent compression member coupled with the sleeve between the first and second heat delivery members.

Growing community of inventors

Palo Alto, CA, United States of America

Ritu Lal